Neurocrine Biosciences (Brazil) Investor Sentiment

N1BI34 Stock   33.14  0.78  2.30%   
About 62% of Neurocrine Biosciences' investor base is looking to short. The analysis of current outlook of investing in Neurocrine Biosciences suggests that many traders are alarmed regarding Neurocrine Biosciences' prospects. The current market sentiment, together with Neurocrine Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Neurocrine Biosciences stock news signals to limit their universe of possible portfolio assets.
  
over a month ago at news.google.com         
NBIX - Neurocrine Biosciences Inc Latest Stock News Market Updates - StockTitan
Google News at Macroaxis
over a month ago at news.google.com         
Needham Company LLC Reaffirms Hold Rating for Neurocrine Biosciences - MarketBeat
Google News at Macroaxis
over two months ago at news.google.com         
Neurocrine Biosciences SWOT analysis stock faces mixed pipeline results, regulatory challenges - Inv...
Google News at Macroaxis
over two months ago at news.google.com         
XTX Topco Ltd Purchases 5,322 Shares of Neurocrine Biosciences, Inc. - MarketBeat
Google News at Macroaxis
over two months ago at news.google.com         
Neurocrine Biosciences, Inc. Shares Sold by Fmr LLC - MarketBeat
Google News at Macroaxis
over two months ago at news.google.com         
State Street Corp Grows Position in Neurocrine Biosciences, Inc. - MarketBeat
Google News at Macroaxis
over two months ago at news.google.com         
Why Is Neurocrine Biosciences, Inc. Among the Best High Growth Healthcare Stocks to Invest In Now - ...
Google News at Macroaxis
over two months ago at news.google.com         
Advisors Asset Management Inc. Purchases 4,549 Shares of Neurocrine Biosciences, Inc. - MarketBeat
Google News at Macroaxis
over two months ago at news.google.com         
Intech Investment Management LLC Raises Stock Position in Neurocrine Biosciences, Inc. - MarketBeat
Google News at Macroaxis
over two months ago at news.google.com         
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has 94.48 Million Stake in Neurocrine Biosciences, Inc. - ...
Google News at Macroaxis
over three months ago at news.google.com         
Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels - Seeking Alpha
Google News at Macroaxis
over three months ago at news.google.com         
Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales G...
Google News at Macroaxis
over three months ago at news.google.com         
Implied Volatility Surging for Neurocrine Biosciences Stock Options - Yahoo Finance
Google News at Macroaxis
over three months ago at news.google.com         
The Play On Neurocrine Biosciences - Seeking Alpha
Google News at Macroaxis
over three months ago at news.google.com         
Perceptive Advisors LLC Cuts Holdings in Neurocrine Biosciences, Inc. - MarketBeat
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Neurocrine Biosciences that are available to investors today. That information is available publicly through Neurocrine media outlets and privately through word of mouth or via Neurocrine internal channels. However, regardless of the origin, that massive amount of Neurocrine data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Neurocrine Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Neurocrine Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Neurocrine Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Neurocrine Biosciences alpha.

Neurocrine Biosciences Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Neurocrine Stock analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years